JP2004517948A - 移植器官の拒絶反応の治療および予防における（ｒ）−イブプロフェンメタンスルホンアミドおよびその塩の使用 - Google Patents

移植器官の拒絶反応の治療および予防における（ｒ）−イブプロフェンメタンスルホンアミドおよびその塩の使用 Download PDF

Info

Publication number
JP2004517948A
JP2004517948A JP2002562337A JP2002562337A JP2004517948A JP 2004517948 A JP2004517948 A JP 2004517948A JP 2002562337 A JP2002562337 A JP 2002562337A JP 2002562337 A JP2002562337 A JP 2002562337A JP 2004517948 A JP2004517948 A JP 2004517948A
Authority
JP
Japan
Prior art keywords
ischemia
hours
methanesulfonamide
salt
transplantation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002562337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517948A5 (enExample
Inventor
ベルティーニ，リッカルド
コロッタ，フランセスコ
ノベッリーニ，ロベルト
Original Assignee
ドムペ・ソチエタ・ペル・アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドムペ・ソチエタ・ペル・アツィオーニ filed Critical ドムペ・ソチエタ・ペル・アツィオーニ
Publication of JP2004517948A publication Critical patent/JP2004517948A/ja
Publication of JP2004517948A5 publication Critical patent/JP2004517948A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2002562337A 2001-02-02 2002-01-30 移植器官の拒絶反応の治療および予防における（ｒ）−イブプロフェンメタンスルホンアミドおよびその塩の使用 Pending JP2004517948A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (2)

Publication Number Publication Date
JP2004517948A true JP2004517948A (ja) 2004-06-17
JP2004517948A5 JP2004517948A5 (enExample) 2005-12-22

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002562337A Pending JP2004517948A (ja) 2001-02-02 2002-01-30 移植器官の拒絶反応の治療および予防における（ｒ）−イブプロフェンメタンスルホンアミドおよびその塩の使用

Country Status (26)

Country Link
US (1) US7560487B2 (enExample)
EP (1) EP1355641B1 (enExample)
JP (1) JP2004517948A (enExample)
KR (1) KR100857898B1 (enExample)
CN (1) CN1561205A (enExample)
AT (1) ATE304846T1 (enExample)
AU (1) AU2002250869B2 (enExample)
BR (2) BRPI0206804B1 (enExample)
CA (1) CA2432432C (enExample)
CZ (1) CZ303665B6 (enExample)
DE (1) DE60206245T2 (enExample)
DK (1) DK1355641T3 (enExample)
EE (1) EE05233B1 (enExample)
ES (1) ES2248541T3 (enExample)
HU (1) HU229070B1 (enExample)
IL (1) IL157180A (enExample)
IT (1) ITMI20010206A1 (enExample)
MX (1) MXPA03006686A (enExample)
NO (1) NO334285B1 (enExample)
NZ (1) NZ526655A (enExample)
PL (1) PL215109B1 (enExample)
PT (1) PT1355641E (enExample)
RU (1) RU2257895C2 (enExample)
SK (1) SK287632B6 (enExample)
WO (1) WO2002062330A2 (enExample)
ZA (1) ZA200304861B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506704A (ja) * 2009-10-06 2013-02-28 ドムペ・ソチエタ・ペル・アツィオーニ ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004003673T2 (de) * 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
HUE065802T2 (hu) * 2017-03-15 2024-06-28 Numares Ag Marker-készlet alkalmazása vesekilökõdés kockázatának meghatározására

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
RU2008901C1 (ru) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Способ фармакологической защиты децентрализованной почки
ATE257389T1 (de) * 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506704A (ja) * 2009-10-06 2013-02-28 ドムペ・ソチエタ・ペル・アツィオーニ ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬
JP2015145404A (ja) * 2009-10-06 2015-08-13 ドムペ・ソチエタ・ペル・アツィオーニ ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬

Also Published As

Publication number Publication date
PL363576A1 (en) 2004-11-29
EE05233B1 (et) 2009-12-15
ZA200304861B (en) 2004-06-30
IL157180A (en) 2009-06-15
RU2003126600A (ru) 2005-02-27
MXPA03006686A (es) 2004-05-31
NO20033273D0 (no) 2003-07-18
ES2248541T3 (es) 2006-03-16
PT1355641E (pt) 2005-11-30
HU229070B1 (hu) 2013-07-29
SK9732003A3 (en) 2003-11-04
BRPI0206804B1 (pt) 2018-09-25
US7560487B2 (en) 2009-07-14
CA2432432A1 (en) 2002-08-15
HUP0303024A2 (hu) 2003-12-29
DE60206245T2 (de) 2006-06-14
NO20033273L (no) 2003-07-18
SK287632B6 (sk) 2011-04-05
NO334285B1 (no) 2014-01-27
WO2002062330A2 (en) 2002-08-15
EP1355641B1 (en) 2005-09-21
NZ526655A (en) 2005-02-25
RU2257895C2 (ru) 2005-08-10
EE200300340A (et) 2003-10-15
EP1355641A2 (en) 2003-10-29
WO2002062330A3 (en) 2003-04-03
CZ303665B6 (cs) 2013-02-20
DK1355641T3 (da) 2005-10-17
AU2002250869B2 (en) 2006-10-19
CN1561205A (zh) 2005-01-05
PL215109B1 (pl) 2013-10-31
CA2432432C (en) 2008-03-25
CZ20032095A3 (en) 2004-05-12
KR100857898B1 (ko) 2008-09-10
BR0206804A (pt) 2004-02-03
ATE304846T1 (de) 2005-10-15
KR20030074725A (ko) 2003-09-19
US20040102520A1 (en) 2004-05-27
ITMI20010206A1 (it) 2002-08-02
HUP0303024A3 (en) 2005-07-28
DE60206245D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
EP4126905B1 (en) Cyclophilin inhibitors and uses thereof
CZ330896A3 (cs) Použití látky, která brání nebo minimalizuje oxidaci polynenasycené mastné kyseliny a způsoby s tímto použitím spojené
JP2829440B2 (ja) Ｏ▲上６▼―アルキルグアニン―ｄｎａアルキルトランスフェラーゼ減少化活性を有するｏ▲上６▼―ベンジル化グアニン、グアノシンおよび２′―デオキシグアノシン化合物
JPH01313428A (ja) 免疫抑制剤として有用な４‐キノリンカルボン酸誘導体
EP3655012A1 (en) Cyclosporin analogues and uses thereof
EP1355641B1 (en) Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
AU2002250869A1 (en) Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
Hertle et al. Calcium channel blocker nisoldipine limits ischemic damage in rat kidney
CA3015432A1 (en) Ambrisentan for use in the treatment of acute renal failure
Sato et al. Endogenous asymmetrical dimethylarginine and hypertension associated with puromycin nephrosis in the rat
KR950008206B1 (ko) 2-클로로-4-((시아노메틸)티오)페닐 n-메틸 카바메이트 및 이의 제조방법, 및 이를 함유하는 약제학적 조성물
Adler et al. Factors influencing the progression of renal insufficiency
HK1071853A (en) Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
JPS6224406B2 (enExample)
NZ786075A (en) Ambrisentan for use in the treatment of acute renal failure
HK1176001A (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
JPH1112174A (ja) 発癌抑制剤
CN101466367A (zh) 治疗肾病的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041001

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080924